Rapport Therapeutics, Inc. Common Stock (RAPP)
Publicly reported company facts and saved market data for Rapport Therapeutics, Inc. Common Stock (RAPP), with sources and as-of times. Saved data is not a live quote.
Company profile
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The Company's founders made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain, which form the basis of Rapport's RAP technology platform. The platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport's precision neuroscience pipeline includes the Company's lead investigational drug, RAP-219, which is designed to achieve neuroanatomical specificity through selective targeting of a RAP expressed only in discrete regions of the brain. The pipeline is anchored by the Company's epilepsy portfolio, including FOS and primary generalized tonic-clonic seizures, as well as bipolar mania.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $1.2B · as of
- Incorporated in
- United States
- Company website
- www.rapportrx.com
- Exchange
- NASDAQ
Saved quote
Saved snapshot, not a real-time quote. Check the market time before relying on it.
- Last reported price
- $25.74
- Reported change
- +6.32%
- Reported volume
- 926,555
- Latest market time
Float and shares outstanding
| Measure | Shares | As of | Source and basis |
|---|---|---|---|
| Float F01 | 28,057,702 | Reported by a single source; not cross-checked. | |
| Historical float F02 | 1,003,058 | Historical estimate from the SEC-disclosed public float value; not current tradable shares. | |
| Shares outstanding (O/S) | 47,978,286 | SEC 10-Q filing · filed |
Dates are measurement dates, not the time FennEdge retrieved the data. Float references are listed separately; they are not averaged or adjusted for later splits or share issuances.
Short interest
- Reported short interest
- 3,051,500 shares
- Settlement date
- Source
- Market and company data
Exchange-published short interest for the stated settlement date, not a live short position.
Recent daily sessions
The 10 most recent saved daily sessions, through . Daily OHLC and volume; not real-time.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 22.58 | 25.75 | 22.51 | 24.21 | 3,096,810 | |
| 22.55 | 23.94 | 22.06 | 22.50 | 5,960,886 | |
| 25.11 | 28.31 | 25.11 | 27.54 | 703,926 | |
| 26.02 | 27.95 | 25.08 | 25.33 | 1,041,210 | |
| 27.54 | 27.76 | 25.70 | 25.93 | 1,185,460 | |
| 26.17 | 27.89 | 25.80 | 26.53 | 1,459,476 | |
| 29.91 | 29.91 | 24.69 | 25.06 | 2,161,677 | |
| 30.33 | 31.31 | 26.73 | 29.37 | 8,206,631 | |
| 27.57 | 29.10 | 27.57 | 28.60 | 300,734 | |
| 29.50 | 29.75 | 26.93 | 27.57 | 413,607 |
Dilution timeline
As of
- · FWP · Free writing prospectus filed
- · FWP · Free writing prospectus filed
- · FWP · Free writing prospectus filed
- · FWP · Free writing prospectus filed
- · 424B5 · Prospectus filed
- · 424B5 · Prospectus filed
- · 10-Q · Periodic report filed
- · S-3ASR · Shelf registration filed
Parsed share counts, prices and warrant terms require Plus or above. Explore plans
Research this company
FennEdge organizes SEC filings and reported market data. Sign in for additional research and your private trading context.
Sign in to continue